1
|
Dafoe TJ, Dos Santos T, Spigelman AF, Lyon J, Smith N, Bautista A, MacDonald PE, Manning Fox JE. Impacts of the COVID-19 pandemic on a human research islet program. Islets 2022; 14:101-113. [PMID: 35285768 PMCID: PMC8928860 DOI: 10.1080/19382014.2022.2047571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 02/23/2022] [Accepted: 02/24/2022] [Indexed: 11/23/2022] Open
Abstract
Designated a pandemic in March 2020, the spread of severe acute respiratory syndrome virus 2 (SARS-CoV2), the virus responsible for coronavirus disease 2019 (COVID-19), led to new guidelines and restrictions being implemented for individuals, businesses, and societies in efforts to limit the impacts of COVID-19 on personal health and healthcare systems. Here we report the impacts of the COVID-19 pandemic on pancreas processing and islet isolation/distribution outcomes at the Alberta Diabetes Institute IsletCore, a facility specializing in the processing and distribution of human pancreatic islets for research. While the number of organs processed was significantly reduced, organ quality and the function of cellular outputs were minimally impacted during the pandemic when compared to an equivalent period immediately prior. Despite the maintained quality of isolated islets, feedback from recipient groups was more negative. Our findings suggest this is likely due to disrupted distribution which led to increased transit times to recipient labs, particularly those overseas. Thus, to improve overall outcomes in a climate of limited research islet supply, prioritization of tissue recipients based on likely tissue transit times may be needed.
Collapse
Affiliation(s)
- Tina J. Dafoe
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Theodore Dos Santos
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Aliya F. Spigelman
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - James Lyon
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Nancy Smith
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Austin Bautista
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Patrick E. MacDonald
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Jocelyn E. Manning Fox
- Alberta Diabetes Institute IsletCore and Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
2
|
Bicudo E, Brass I. Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of 'point-of-care manufacturing readiness'. Regen Med 2022; 17:719-737. [PMID: 36065826 DOI: 10.2217/rme-2022-0064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: To propose the concept of point-of-care manufacturing readiness for analyzing the capacity that a country, a health system or an institution has developed to manufacture therapies in clinical settings (point-of-care manufacture). The focus is on advanced therapies (cell, gene and tissue engineering therapies) in the UK. Materials & methods: Literature review, analysis of quantitative data, and qualitative interviews with professionals and practitioners developing and administering advanced therapies. Results: Three components of point-of-care manufacturing readiness are analyzed staff and institutional procedures, infrastructure, and relations between hospitals and service providers. Conclusion: The technical and regulatory experience that has been gained through manufacturing advanced therapies at small scale in hospitals qualifies the UK for more complex and larger-scale production of therapies in the future.
Collapse
Affiliation(s)
- Edison Bicudo
- Department of Science, Technology, Engineering, & Public Policy, University College London, Shropshire House (4th Floor), 11-20 Capper Street, London, WC1E 6JA, UK
| | - Irina Brass
- Department of Science, Technology, Engineering, & Public Policy, University College London, Shropshire House (4th Floor), 11-20 Capper Street, London, WC1E 6JA, UK
| |
Collapse
|
3
|
Olack BJ, Alexander M, Swanson CJ, Kilburn J, Corrales N, Flores A, Heng J, Arulmoli J, Omori K, Chlebeck PJ, Zitur L, Salgado M, Lakey JRT, Niland JC. Optimal Time to Ship Human Islets Post Tissue Culture to Maximize Islet. Cell Transplant 2021; 29:963689720974582. [PMID: 33231091 PMCID: PMC7885128 DOI: 10.1177/0963689720974582] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Access to functional high-quality pancreatic human islets is critical to advance diabetes research. The Integrated Islet Distribution Program (IIDP), a major source for human islet distribution for over 15 years, conducted a study to evaluate the most advantageous times to ship islets postisolation to maximize islet recovery. For the evaluation, three experienced IIDP Islet Isolation Centers each provided samples from five human islet isolations, shipping 10,000 islet equivalents (IEQ) at four different time periods postislet isolation (no 37°C culture and shipped within 0 to 18 hours; or held in 37°C culture for 18 to 42, 48 to 96, or 144 to 192 hours). A central evaluation center compared samples for islet quantity, quality, and viability for each experimental condition preshipment and postshipment, as well as post 37°C culture 18 to 24 hours after shipment receipt. Additional evaluations included measures of functional potency by static glucose-stimulated insulin release (GSIR), represented as a stimulation index. Comparing the results of the four preshipment holding periods, the greatest IEQ loss postshipment occurred with the shortest preshipment times. Similar patterns emerged when comparing preshipment to postculture losses. In vitro islet function (GSIR) was not adversely impacted by increased tissue culture time. These data indicate that allowing time for islet recovery postisolation, prior to shipping, yields less islet loss during shipment without decreasing islet function.
Collapse
Affiliation(s)
- Barbara J Olack
- Integrated Islet Distribution Program, Department of Diabetes & Cancer Discovery Science, City of Hope, Duarte, CA, USA
| | - Michael Alexander
- Department of Surgery, University of California Irvine, Orange, CA, USA
| | - Carol J Swanson
- Integrated Islet Distribution Program, Department of Diabetes & Cancer Discovery Science, City of Hope, Duarte, CA, USA
| | - Julie Kilburn
- Integrated Islet Distribution Program, Department of Diabetes & Cancer Discovery Science, City of Hope, Duarte, CA, USA
| | - Nicole Corrales
- Department of Surgery, University of California Irvine, Orange, CA, USA
| | - Antonio Flores
- Department of Surgery, University of California Irvine, Orange, CA, USA
| | - Jennifer Heng
- Department of Surgery, University of California Irvine, Orange, CA, USA
| | | | - Keiko Omori
- Department of Translational Research and Cellular Therapeutics, City of Hope, Duarte, CA, USA
| | - Peter J Chlebeck
- Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Laura Zitur
- Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Mayra Salgado
- Department of Translational Research and Cellular Therapeutics, City of Hope, Duarte, CA, USA
| | - Jonathan R T Lakey
- Department of Surgery, University of California Irvine, Orange, CA, USA.,Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA
| | - Joyce C Niland
- Integrated Islet Distribution Program, Department of Diabetes & Cancer Discovery Science, City of Hope, Duarte, CA, USA
| |
Collapse
|
4
|
Strauss AT, Cartier D, Gunning BA, Boyarsky BJ, Snyder J, Segev DL, Roush M, Massie AB. Impact of the COVID-19 pandemic on commercial airlines in the United States and implications for the kidney transplant community. Am J Transplant 2020; 20:3123-3130. [PMID: 32860307 PMCID: PMC9800715 DOI: 10.1111/ajt.16284] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 08/12/2020] [Accepted: 08/19/2020] [Indexed: 01/25/2023]
Abstract
Many deceased-donor and living-donor kidney transplants (KTs) rely on commercial airlines for transport. However, the coronavirus-19 pandemic has drastically impacted the commercial airline industry. To understand potential pandemic-related disruptions in the transportation network of kidneys across the United States, we used national flight data to compare scheduled flights during the pandemic vs 1-year earlier, focusing on Organ Procurement Organization (OPO) pairs between which kidneys historically most likely traveled by direct flight (High Volume by direct Air transport OPO Pairs, HVA-OPs). Across the United States, there were 39% fewer flights in April 2020 vs April 2019. Specific to the kidney transportation network, there were 65.1% fewer flights between HVA-OPs, with considerable OPO-level variation (interquartile range [IQR] 54.7%-75.3%; range 0%-100%). This translated to a drop in median number of flights between HVA-OPs from 112 flights/wk in April 2019 to 34 in April 2020 (P < .001), and a rise in wait time between scheduled flights from 1.5 hours in April 2019 (IQR 0.76-3.3) to 4.9 hours in April 2020 (IQR 2.6-11.2; P < .001). Fewer flights and longer wait times can impact logistics as well as cold ischemia time; our findings motivate an exploration of creative approaches to KT transport as the impact of this pandemic on the airline industry evolves.
Collapse
Affiliation(s)
- Alexandra T. Strauss
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | | | | | - Brian J. Boyarsky
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Jon Snyder
- Scientific Registry of Transplant Recipients, Minneapolis, Minnesota, USA
| | - Dorry L. Segev
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA,Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA,Scientific Registry of Transplant Recipients, Minneapolis, Minnesota, USA,Correspondence Dorry L. Segev
| | | | - Allan B. Massie
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA,Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA
| |
Collapse
|
5
|
Brissova M, Niland JC, Cravens J, Olack B, Sowinski J, Evans-Molina C. The Integrated Islet Distribution Program answers the call for improved human islet phenotyping and reporting of human islet characteristics in research articles. Diabetologia 2019; 62:1312-1314. [PMID: 31089753 PMCID: PMC7365209 DOI: 10.1007/s00125-019-4876-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Accepted: 04/01/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Marcela Brissova
- Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Joyce C Niland
- Department of Diabetes and Cancer Discovery Science, Diabetes and Metabolism Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
| | - James Cravens
- Department of Diabetes and Cancer Discovery Science, Diabetes and Metabolism Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA
| | - Barbara Olack
- Department of Diabetes and Cancer Discovery Science, Diabetes and Metabolism Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA
| | - Janice Sowinski
- Department of Diabetes and Cancer Discovery Science, Diabetes and Metabolism Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA
| | - Carmella Evans-Molina
- Department of Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Room 2031, Indianapolis, IN, 46202, USA.
- Roudebush VA Medical Center, Indianapolis, IN, USA.
| |
Collapse
|
6
|
Brissova M, Niland JC, Cravens J, Olack B, Sowinski J, Evans-Molina C. The Integrated Islet Distribution Program Answers the Call for Improved Human Islet Phenotyping and Reporting of Human Islet Characteristics in Research Articles. Diabetes 2019; 68:1363-1365. [PMID: 31092479 PMCID: PMC6609985 DOI: 10.2337/dbi19-0019] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Accepted: 04/05/2019] [Indexed: 01/04/2023]
Affiliation(s)
- Marcela Brissova
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Joyce C Niland
- Department of Diabetes & Cancer Discovery Science, Diabetes & Metabolism Research Institute at City of Hope, Duarte, CA
| | - James Cravens
- Department of Diabetes & Cancer Discovery Science, Diabetes & Metabolism Research Institute at City of Hope, Duarte, CA
| | - Barbara Olack
- Department of Diabetes & Cancer Discovery Science, Diabetes & Metabolism Research Institute at City of Hope, Duarte, CA
| | - Janice Sowinski
- Department of Diabetes & Cancer Discovery Science, Diabetes & Metabolism Research Institute at City of Hope, Duarte, CA
| | - Carmella Evans-Molina
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
- Roudebush VA Medical Center, Indianapolis, IN
| |
Collapse
|
7
|
Hart NJ, Powers AC. Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions. Diabetologia 2019; 62:212-222. [PMID: 30547228 PMCID: PMC6325002 DOI: 10.1007/s00125-018-4772-2] [Citation(s) in RCA: 103] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 09/24/2018] [Indexed: 02/07/2023]
Abstract
Over the last two decades, improved access to human islets and the development of human islet distribution networks have enabled the use of millions of human islets in hundreds of scientific research projects, leading to a dramatic increase in our understanding of human islet biology. Here we discuss recent scientific advances as well as methodological and experimental challenges that impact human islet quality, experimental outcomes and the reporting of human islets used in scientific publications. In a survey of over 200 scientific publications with human islet experimentation, we found that the reporting of critical information was quite variable, sometimes obscure, and often failed to adequately outline the experiments and results using human islets. As the complexity of human islet research grows, we propose that members of the human islet research ecosystem work together to develop procedures and approaches for accessible and transparent collecting and reporting of crucial human islet characteristics and, through this, enhance collaboration, reproducibility and rigour, leading to further advances in our understanding of human islet biology.
Collapse
Affiliation(s)
- Nathaniel J Hart
- Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, 7465 Medical Research Bldg IV, Vanderbilt University Medical Center, 2215 Garland Avenue, Nashville, TN, 37232-0475, USA
- Institute for Cellular Transplantation, College of Medicine, Department of Surgery, Arizona Health Sciences Center, Tucson, AZ, USA
| | - Alvin C Powers
- Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, 7465 Medical Research Bldg IV, Vanderbilt University Medical Center, 2215 Garland Avenue, Nashville, TN, 37232-0475, USA.
- Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA.
- VA Tennessee Valley Healthcare, Nashville, TN, USA.
| |
Collapse
|
8
|
Beißner N, Zorn-Kruppa M, Reichl S. Parameter study of shipping conditions for the ready-to-use application of a 3D human hemicornea construct in drug absorption studies. Int J Pharm 2018; 536:377-387. [PMID: 29191484 DOI: 10.1016/j.ijpharm.2017.11.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 11/24/2017] [Accepted: 11/25/2017] [Indexed: 10/18/2022]
Abstract
In this study, a shipping protocol for our 3D human hemicornea (HC) construct should be developed to provide quality-maintaining shipping conditions and to allow its ready-to-use application in drug absorption studies. First, the effects of single and multiple parameters, such as the type of shipping container, storage temperature and CO2 supply, were investigated under controlled laboratory conditions by assessing cell viability via MTT dye reaction and epithelial barrier properties via transepithelial electrical resistance (TEER) measurements. These investigations showed that TEER is more susceptible to shipping parameters than cell viability. Furthermore, the results were used to determine the optimal shipping conditions and critical values for subsequent overnight, real-time shipping experiments. Epithelial barrier properties were then investigated via TEER and the permeation of sodium fluorescein for shipped and not shipped HC. The results underscore that acceleration forces and changes in position may have a great impact on the epithelial barrier of 3D models. Low acceleration values and short changes in position caused only minor impairments. However, combined or intensive separate effects resulted in considerably low yields after shipping. Consequently, barrier-maintaining shipping of 3D in vitro models seems to be challenging, as mechanical forces have to be reduced to a minimum.
Collapse
Affiliation(s)
- Nicole Beißner
- Institut für Pharmazeutische Technologie, Technische Universität Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig, Germany; Center of Pharmaceutical Engineering - PVZ, Technische Universität Braunschweig, Franz-Liszt-Straße 35 A, 38106 Braunschweig, Germany
| | - Michaela Zorn-Kruppa
- Klinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Stephan Reichl
- Institut für Pharmazeutische Technologie, Technische Universität Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig, Germany; Center of Pharmaceutical Engineering - PVZ, Technische Universität Braunschweig, Franz-Liszt-Straße 35 A, 38106 Braunschweig, Germany.
| |
Collapse
|
9
|
Forget A, Staehly C, Ninan N, Harding FJ, Vasilev K, Voelcker NH, Blencowe A. Oxygen-Releasing Coatings for Improved Tissue Preservation. ACS Biomater Sci Eng 2017; 3:2384-2390. [DOI: 10.1021/acsbiomaterials.7b00297] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Aurelien Forget
- School of Pharmacy
and Medical Sciences, University of South Australia, Adelaide, South Australia 5000, Australia
- Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM), Adelaide, South Australia 5000, Australia
- School of Chemistry,
Physics and Mechanical Engineering, Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland 4001, Australia
| | - Camille Staehly
- Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM), Adelaide, South Australia 5000, Australia
- Future
Industries Institute, University of South Australia, Mawson
Lakes, South Australia 5095, Australia
| | - Neethu Ninan
- School of Pharmacy
and Medical Sciences, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Frances J. Harding
- Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM), Adelaide, South Australia 5000, Australia
- Cell Therapies Pty Ltd, Victorian Comprehensive Cancer Centre (VCCC), Melbourne, Victoria 3000, Australia
| | - Krasimir Vasilev
- Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM), Adelaide, South Australia 5000, Australia
- Future
Industries Institute, University of South Australia, Mawson
Lakes, South Australia 5095, Australia
- School of Engineering, University of South Australia, Mawson Lakes, South Australia 5095, Australia
| | - Nicolas H. Voelcker
- Future
Industries Institute, University of South Australia, Mawson
Lakes, South Australia 5095, Australia
- Monash
Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO), Clayton, Victoria 3168, Australia
| | - Anton Blencowe
- School of Pharmacy
and Medical Sciences, University of South Australia, Adelaide, South Australia 5000, Australia
- Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM), Adelaide, South Australia 5000, Australia
- Future
Industries Institute, University of South Australia, Mawson
Lakes, South Australia 5095, Australia
| |
Collapse
|
10
|
Martinez-Gamboa M, Cruz-Vega DE, Moreno-Cuevas J, Gonzalez-Garza MT. Induction of Nestin Early Expression as a Hallmark for Mesenchymal Stem Cells Expression of PDX-1 as a Pre-disposing Factor for Their Conversion into Insulin Producing Cells. Int J Stem Cells 2017; 10:76-82. [PMID: 28024317 PMCID: PMC5488779 DOI: 10.15283/ijsc16040] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2016] [Indexed: 12/18/2022] Open
Abstract
Diabetes constitutes a worldwide epidemic that affects all ethnic groups. Cell therapy is one of the best alternatives of treatment, by providing an effective way to regenerate insulin-producing cells lost during the course of the disease, but many issues remain to be solved. Several groups have been working in the development of a protocol capable of differentiating Mesenchymal Stem Cells (MSCs) into physiologically sound Insulin Producing Cells (IPCs). In order to obtain a simple, fast and direct method, we propose in this manuscript the induction of MSCs to express NESTIN in a short time period (2 h), proceeded by incubation in a low glucose induced medium (24 h) and lastly by incubation in a high glucose medium. Samples from cell cultures incubated in high glucose medium from 12 to 168 h were obtained to detect the expression of INSULIN-1, INSULIN -2, PDX-1 and GLUT-2 genes. Induced cells were exposed to a glucose challenge, in order to assess the production of insulin. This method allowed us to obtain cells expressing PDX-1, which resembles a progenitor insulin-producing cell.
Collapse
Affiliation(s)
- Marisela Martinez-Gamboa
- Escuela De Ciencias De La Salud, Valle de las Palmas, Universidad Autónoma de Baja California, Tijuana, B.C, CP 22263, México.,Cell Therapy Group, Escuela Nacional De Medicina, Tecnológico de Monterrey, Monterrey, CP 64710, NL, México
| | - Delia Elba Cruz-Vega
- Cell Therapy Group, Escuela Nacional De Medicina, Tecnológico de Monterrey, Monterrey, CP 64710, NL, México
| | - Jorge Moreno-Cuevas
- Cell Therapy Group, Escuela Nacional De Medicina, Tecnológico de Monterrey, Monterrey, CP 64710, NL, México
| | | |
Collapse
|
11
|
Wong WP, Allen NB, Meyers MS, Link EO, Zhang X, MacRenaris KW, El Muayed M. Exploring the Association Between Demographics, SLC30A8 Genotype, and Human Islet Content of Zinc, Cadmium, Copper, Iron, Manganese and Nickel. Sci Rep 2017; 7:473. [PMID: 28352089 PMCID: PMC5428289 DOI: 10.1038/s41598-017-00394-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Accepted: 02/23/2017] [Indexed: 12/30/2022] Open
Abstract
A widely prevalent single nucleotide polymorphism, rs13266634 in the SLC30A8 gene encoding the zinc transporter ZnT8, is associated with an increased risk for T2DM. ZnT8 is mostly expressed in pancreatic insulin-producing islets of Langerhans. The effect of this variant on the divalent metal profile in human islets is unknown. Additionally, essential and non-essential divalent metal content of human islets under normal environmental exposure conditions has not been described. We therefore examined the correlation of zinc and other divalent metals in human islets with rs13266634 genotype and demographic characteristics. We found that the diabetes risk genotype C/C at rs13266634 is associated with higher islet Zn concentration (C/C genotype: 16792 ± 1607, n = 22, C/T genotype: 11221 ± 1245, n = 18 T/T genotype: 11543 ± 6054, n = 3, all values expressed as mean nmol/g protein ± standard error of the mean, p = 0.040 by ANOVA). A positive correlation between islet cadmium content and both age (p = 0.048, R2 = 0.09) and female gender (women: 36.88 ± 4.11 vs men: 21.22 ± 3.65 nmol/g protein, p = 0.007) was observed. Our results suggest that the T2DM risk allele C is associated with higher islet zinc levels and support prior evidence of cadmium's higher bioavailability in women and its long tissue half-life.
Collapse
Affiliation(s)
- Winifred P Wong
- Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
| | - Norrina B Allen
- Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
| | - Matthew S Meyers
- Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
| | - Emma O Link
- Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
| | - Xiaomin Zhang
- Division of Transplant Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
| | - Keith W MacRenaris
- The Chemistry of Life Processes Institute and Department of Chemistry, Northwestern University, Evanston, IL, 60208, USA
| | - Malek El Muayed
- Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
| |
Collapse
|
12
|
Dorrell C, Schug J, Canaday PS, Russ HA, Tarlow BD, Grompe MT, Horton T, Hebrok M, Streeter PR, Kaestner KH, Grompe M. Human islets contain four distinct subtypes of β cells. Nat Commun 2016; 7:11756. [PMID: 27399229 PMCID: PMC4942571 DOI: 10.1038/ncomms11756] [Citation(s) in RCA: 253] [Impact Index Per Article: 31.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Accepted: 04/27/2016] [Indexed: 01/10/2023] Open
Abstract
Human pancreatic islets of Langerhans contain five distinct endocrine cell types, each producing a characteristic hormone. The dysfunction or loss of the insulin-producing β cells causes diabetes mellitus, a disease that harms millions. Until now, β cells were generally regarded as a single, homogenous cell population. Here we identify four antigenically distinct subtypes of human β cells, which we refer to as β1–4, and which are distinguished by differential expression of ST8SIA1 and CD9. These subpopulations are always present in normal adult islets and have diverse gene expression profiles and distinct basal and glucose-stimulated insulin secretion. Importantly, the β cell subtype distribution is profoundly altered in type 2 diabetes. These data suggest that this antigenically defined β cell heterogeneity is functionally and likely medically relevant. Dysfunction or loss of insulin-secreting β cells in the pancreas is a hallmark of diabetes. Here, Dorrell et al. identify four subpopulations of β cells in humans, which differ in gene expression and insulin secretion kinetics, and the abundance of which is altered in patients with type 2 diabetes.
Collapse
Affiliation(s)
- Craig Dorrell
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Jonathan Schug
- Department of Genetics and Institute for Diabetes, Obesity, and Metabolism; University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
| | - Pamela S Canaday
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Holger A Russ
- Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, California 94143, USA
| | - Branden D Tarlow
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Maria T Grompe
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Tamara Horton
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Matthias Hebrok
- Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, California 94143, USA
| | - Philip R Streeter
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| | - Klaus H Kaestner
- Department of Genetics and Institute for Diabetes, Obesity, and Metabolism; University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
| | - Markus Grompe
- Oregon Stem Cell Center, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
| |
Collapse
|
13
|
Harlan DM. Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor. Diabetes Care 2016; 39:1072-4. [PMID: 27330121 DOI: 10.2337/dci16-0008] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- David M Harlan
- Diabetes Center of Excellence, Department of Medicine, University of Massachusetts Medical School, Worcester, MA
| |
Collapse
|
14
|
Ghorbani R, Jalili C, Salahshoor MR, Shiasi M. The effect of time and temperature on viability and performance of Langerhans islets separated from Balb/c mouse after death. Adv Biomed Res 2015; 4:93. [PMID: 26015919 PMCID: PMC4434490 DOI: 10.4103/2277-9175.156657] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Accepted: 06/11/2014] [Indexed: 12/14/2022] Open
Abstract
Background: Tissue transplantation plays a pivotal role in the treatment of diseases. Pancreatic beta cell transplantation is the best way to obtain normal blood glucose in patients with diabetes type 1. However, it is not clear how long endocrine pancreas cells can be used for transplantation after the donor's death. The present study was conducted to analyze the performance and viability of pancreatic islet cells after death. Materials and Methods: Pancreas was separated from Balb/c mice at different times (0, 1, 4, 6, 12, and 24 h after death) at temperatures of 4°C and 23°C, and was cultured in Roswell_Park_Memorial_Institute (RPMI) 1640. Insulin shock, MTT assay, aldehyde fuchsin staining, dithizone staining, and florescence microscopy methods were applied to analyze the performance of beta cells, cell viability, islets’ diagnosis, islet cells’ diagnosis, and viable and necrotic cells diagnosis, respectively. Results: Islets of Langerhans and beta cells were diagnosed. By increasing the temperature and time, the viability and performance of beta cells decreased significantly (P < 0.05). Conclusion: The best condition for keeping the islets of Langerhans in terms of viability and performance is 4 h after death at temperature of 4°C.
Collapse
Affiliation(s)
- Rostam Ghorbani
- Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Cyrus Jalili
- Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Mohammad Reza Salahshoor
- Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Maryam Shiasi
- Department of Anatomy, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
15
|
Kayton NS, Poffenberger G, Henske J, Dai C, Thompson C, Aramandla R, Shostak A, Nicholson W, Brissova M, Bush WS, Powers AC. Human islet preparations distributed for research exhibit a variety of insulin-secretory profiles. Am J Physiol Endocrinol Metab 2015; 308:E592-602. [PMID: 25648831 PMCID: PMC4385877 DOI: 10.1152/ajpendo.00437.2014] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Accepted: 01/30/2015] [Indexed: 12/21/2022]
Abstract
Human islet research is providing new insights into human islet biology and diabetes, using islets isolated at multiple US centers from donors with varying characteristics. This creates challenges for understanding, interpreting, and integrating research findings from the many laboratories that use these islets. In what is, to our knowledge, the first standardized assessment of human islet preparations from multiple isolation centers, we measured insulin secretion from 202 preparations isolated at 15 centers over 11 years and noted five distinct patterns of insulin secretion. Approximately three quarters were appropriately responsive to stimuli, but one quarter were dysfunctional, with unstable basal insulin secretion and/or an impairment in stimulated insulin secretion. Importantly, the patterns of insulin secretion by responsive human islet preparations (stable Baseline and Fold stimulation of insulin secretion) isolated at different centers were similar and improved slightly over the years studied. When all preparations studied were considered, basal and stimulated insulin secretion did not correlate with isolation center, biological differences of the islet donor, or differences in isolation, such as Cold Ischemia Time. Dysfunctional islet preparations could not be predicted from the information provided by the isolation center and had altered expression of genes encoding components of the glucose-sensing pathway, but not of insulin production or cell death. These results indicate that insulin secretion by most preparations from multiple centers is similar but that in vitro responsiveness of human islets cannot be predicted, necessitating preexperimental human islet assessment. These results should be considered when one is designing, interpreting, and integrating experiments using human islets.
Collapse
Affiliation(s)
- Nora S Kayton
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Gregory Poffenberger
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Joseph Henske
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Chunhua Dai
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Courtney Thompson
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Radhika Aramandla
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Alena Shostak
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Wendell Nicholson
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Marcela Brissova
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - William S Bush
- Center for Human Genetics Research, Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee; and
| | - Alvin C Powers
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee; Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee
| |
Collapse
|
16
|
Lee S, Takahashi Y, Lee K, Mizuno M, Nemeno J, Takebe T, Lee J. Viability and Functional Assessment of Murine Pancreatic Islets After Transportation Between Korea and Japan. Transplant Proc 2015; 47:738-41. [DOI: 10.1016/j.transproceed.2014.12.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Accepted: 12/31/2014] [Indexed: 11/25/2022]
|
17
|
Kitzmann JP, Pepper AR, Lopez BG, Pawlick R, Kin T, O’Gorman D, Mueller KR, Gruessner AC, Avgoustiniatos ES, Karatzas T, Szot GL, Posselt AM, Stock PG, Wilson JR, Shapiro AM, Papas KK. Human islet viability and function is maintained during high-density shipment in silicone rubber membrane vessels. Transplant Proc 2014; 46:1989-91. [PMID: 25131090 PMCID: PMC4169700 DOI: 10.1016/j.transproceed.2014.06.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND The shipment of human islets (IE) from processing centers to distant laboratories is beneficial for both research and clinical applications. The maintenance of islet viability and function in transit is critically important. Gas-permeable silicone rubber membrane (SRM) vessels reduce the risk of hypoxia-induced death or dysfunction during high-density islet culture or shipment. SRM vessels may offer additional advantages: they are cost-effective (fewer flasks, less labor needed), safer (lower contamination risk), and simpler (culture vessel can also be used for shipment). METHOD IE were isolated from two manufacturing centers and shipped in 10-cm(2) surface area SRM vessels in temperature- and pressure-controlled containers to a distant center after at least 2 days of culture (n = 6). Three conditions were examined: low density (LD), high density (HD), and a microcentrifuge tube negative control (NC). LD was designed to mimic the standard culture density for IE preparations (200 IE/cm(2)), while HD was designed to have a 20-fold higher tissue density, which would enable the culture of an entire human isolation in 1-3 vessels. Upon receipt, islets were assessed for viability (measured by oxygen consumption rate normalized to DNA content [OCR/DNA)]), quantity (measured by DNA), and, when possible, potency and function (measured by dynamic glucose-stimulated insulin secretion measurements and transplants in immunodeficient B6 Rag(+/-) mice). Postshipment OCR/DNA was not reduced in HD vs LD and was substantially reduced in the NC condition. HD islets exhibited normal function postshipment. Based on the data, we conclude that entire islet isolations (up to 400,000 IE) may be shipped using a single, larger SRM vessel with no negative effect on viability and ex vivo and in vivo function.
Collapse
Affiliation(s)
| | - Andrew R Pepper
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Boris G Lopez
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Rena Pawlick
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Tatsuya Kin
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Doug O’Gorman
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Kathryn R Mueller
- Department of Surgery, University of Arizona, Tucson, AZ, United States
| | | | | | - Theodore Karatzas
- Department of Surgery, University of Arizona, Tucson, AZ, United States
- Second Department of Propedeutic Surgery University of Athens, School of Medicine, Athens, Greece
| | - Greg L Szot
- Diabetes Center, University of California, San Francisco, California, United States
| | - Andrew M Posselt
- Diabetes Center, University of California, San Francisco, California, United States
| | - Peter G Stock
- Diabetes Center, University of California, San Francisco, California, United States
| | - John R Wilson
- Wilson Wolf Manufacturing Corporation, New Brighton, Minnesota, United States
| | - AM Shapiro
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | - Klearchos K Papas
- Department of Surgery, University of Arizona, Tucson, AZ, United States
| |
Collapse
|
18
|
Yamashita S, Ohashi K, Utoh R, Kin T, Shapiro AMJ, Yamamoto M, Gotoh M, Okano T. Quality of Air-Transported Human Islets for Single Islet Cell Preparations. CELL MEDICINE 2013; 6:33-8. [PMID: 26858878 DOI: 10.3727/215517913x674243] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
In new generation medical therapies for type 1 diabetes mellitus (DM), cell-based approaches using pancreatic islets have attracted significant attention worldwide. In particular, dispersed islet cells obtained from isolated pancreatic islets have been a valuable source in the cell biology and tissue engineering fields. Our experimental approach to the development of new islet-based DM therapies consisted of creating a monolithic islet cell sheet format using dispersed islet cells. In this experiment, we explored the potential of internationally transporting human islets from Alberta, Canada to Tokyo, Japan and obtaining viable dispersed islet cells. A total of 34 batches of isolated and purified human islets were transported using a commercial air courier service. Prior to shipping, the human islets had been in culture for 0-108 h at the University of Alberta. The transportation period from Alberta to Tokyo was 2-5 days. The transported human islet cells were enzymatically dispersed as single cells in Tokyo. The number of single islet cells decreased as the number of transportation days increased. In contrast, cell viability was maintained regardless of the number of transportation days. The preshipment culture time had no effect on the number or viability of single cells dispersed in Tokyo. When dispersed single islet cells were plated on laminin-5-coated temperature-responsive polymer-grafted culture dishes, the cells showed favorable attachment followed by extension as a monolithic format. The present study demonstrated that long-distance transported human islets are a viable cell source for experiments utilizing dispersed human islet cells.
Collapse
Affiliation(s)
- Shingo Yamashita
- Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University , Tokyo , Japan
| | - Kazuo Ohashi
- Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan; †Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - Rie Utoh
- Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University , Tokyo , Japan
| | - Tatsuya Kin
- ‡ Clinical Islet Transplant Program, University of Alberta , Edmonton, Alberta , Canada
| | - A M James Shapiro
- ‡ Clinical Islet Transplant Program, University of Alberta , Edmonton, Alberta , Canada
| | - Masakazu Yamamoto
- † Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University , Tokyo , Japan
| | - Mitsukazu Gotoh
- § Department of Regenerative Surgery, Fukushima Medical University , Fukushima , Japan
| | - Teruo Okano
- Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University , Tokyo , Japan
| |
Collapse
|